Renaissance Small Cap Growth Strategy Added ADMA Biologics (ADMA) to Its Portfolio in Q2

Group 1: Market Overview - The stock market experienced high volatility in Q2 2025, with a 7% drop in stock prices from April 2 to April 7 due to an unexpected tariff announcement [1] - Following the Trump Administration's retreat from extreme tariff proposals, the market saw a dramatic recovery, supported by sound corporate earnings and solid economic data indicating positive growth ahead [1] - The Russell 2000 Growth Index rallied in Q2 2025, and the Renaissance Investment Small Cap Growth Strategy outperformed this index [1] Group 2: ADMA Biologics, Inc. Overview - ADMA Biologics, Inc. is a commercial-stage biopharmaceutical company focused on plasma-based biologics for immune deficiencies and infectious disease prevention [3] - The company has a significant product, Asceniv, which addresses primary immunodeficiency and has penetrated 3-5% of its target population, with demand currently exceeding supply [3] - ADMA Biologics aims for $1.0 billion in revenue by 2030, more than doubling its projected revenue for 2024 [3] Group 3: Financial Performance - ADMA Biologics reported total revenue of $122 million in Q2 2025, reflecting a 14% year-over-year increase [4] - The stock of ADMA Biologics closed at $15.91 per share on September 19, 2025, with a market capitalization of $3.797 billion [2]